# A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects

> **NCT00134199** · PHASE2,PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 282 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** CP-945,598
- **DRUG:** sibutramine

## Key facts

- **NCT ID:** NCT00134199
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** —
- **Final completion:** 2005-11
- **Target enrollment:** 282 (ACTUAL)
- **Last updated:** 2009-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00134199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00134199, "A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00134199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*